The impact of serum albumin-to-alkaline phosphatase ratio in cervical cancer patients treated with definitive chemoradiotherapy.


Journal

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
ISSN: 1364-6893
Titre abrégé: J Obstet Gynaecol
Pays: England
ID NLM: 8309140

Informations de publication

Date de publication:
Aug 2022
Historique:
pubmed: 3 6 2022
medline: 30 9 2022
entrez: 2 6 2022
Statut: ppublish

Résumé

We retrospectively analysed the prognostic significance of serum albumin, alkaline phosphatase (ALP) and albumin to ALP ratio (AAPR) and other prognostic factors affecting the overall survival (OS) and progression-free survival (PFS) in 200 cervical cancer patients treated with definitive chemoradiotherapy (CRT). The prognostic factors for OS and DFS, in addition to the predictive factors of albumin, ALP and AAPR, were investigated. Older age, lymph node metastasis, non-complete response (CR) to treatment and low serum albumin levels emerged as predictors of poor OS and PFS in multivariate analysis. However, with a cut-off value of 0.51, AAPR was not a significant prognostic factor of survival in multivariable analysis. There were no significant differences in clinicopathological factors between patients with low and high AAPR, except for lymph node metastasis, where lymph node metastasis rate was significantly higher in patients with a low AAPR compared to those with a high AAPR. Patients with CR had a significantly higher serum albumin level and AAPR compared to patients without CR. The pre-treatment serum albumin level was independent predictive for survival; therefore, it could be a suitable biomarker to guide systemic therapy and predict patient outcomes. Impact Statement

Identifiants

pubmed: 35653776
doi: 10.1080/01443615.2022.2069484
doi:

Substances chimiques

Serum Albumin 0
Alkaline Phosphatase EC 3.1.3.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2426-2432

Auteurs

Cem Onal (C)

Department of Radiation Oncology, Adana Dr. Turgut Noyan Research and Treatment Center, Baskent University Faculty of Medicine, Adana, Turkey.
Department of Radiation Oncology, Başkent University Faculty of Medicine, Ankara, Turkey.

Melis Gultekin (M)

Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Guler Yavas (G)

Department of Radiation Oncology, Başkent University Faculty of Medicine, Ankara, Turkey.

Ezgi Oymak (E)

Division of Radiation Oncology, Iskenderun Gelisim Hospital, Iskenderun, Turkey.

Sezin Yuce Sari (S)

Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Ozan Cem Guler (OC)

Department of Radiation Oncology, Adana Dr. Turgut Noyan Research and Treatment Center, Baskent University Faculty of Medicine, Adana, Turkey.

Ecem Yigit (E)

Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Ferah Yildiz (F)

Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH